CA Patent

CA3196923A1 — Oxytocin treatment for hypermobile ehlers-danlos syndrome

Assigned to Baylor College of Medicine · Expires 2022-04-07 · 4y expired

What this patent protects

Embodiments of the present disclosure concern the treatment and/or prevention of Ehlers-Danlos Syndrome (EDS) or its manifestations using therapeutic compositions, such as oxytocin and/or oxytocin analogues. The therapeutic compositions may decrease symptoms and/or reverse diseas…

USPTO Abstract

Embodiments of the present disclosure concern the treatment and/or prevention of Ehlers-Danlos Syndrome (EDS) or its manifestations using therapeutic compositions, such as oxytocin and/or oxytocin analogues. The therapeutic compositions may decrease symptoms and/or reverse disease progression.

Drugs covered by this patent

Patent Metadata

Patent number: CA3196923A1
Jurisdiction: CA
Classification: —
Expires: 2022-04-07
Drug substance claim: No
Drug product claim: No
Assignee: Baylor College of Medicine
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.